A thorough history and physical examination is generally sufficient to allow the practitioner to establish whether the child requires further evaluation (Fig. 1, box 4) or has functional constipation (Fig. 1, box 5).
MANAGEMENT OF CHILDREN WITH FUNCTIONAL CONSTIPATION
The general approach to the child with functional constipation includes the following steps: determine whether fecal impaction is present (Fig. 1, box 6), treat the impaction if present (Fig. 1, box 7), initiate treatment with oral medication, provide parental education and close follow-up, and adjust medications as necessary (Fig. 1, box 10).
The education of the family and the demystification of constipation, including an explanation of the pathogenesis of constipation, are the first steps in treatment. If fecal soiling is present, an important goal for both the child and the parent is to remove negative attributions. It is especially important for parents to understand that soiling from overflow incontinence is not a willful and defiant maneuver. Parents are encouraged to maintain a consistent, positive, and supportive attitude in all aspects of treatment. It may be necessary to repeat the education and demystification processes several times during treatment (18).
Fecal impaction is defined as a hard mass in the lower abdomen identified during physical examination, a dilated rectum filled with a large amount of stool found during rectal examination, or excessive stool in the colon identified by abdominal radiography (19). Disimpaction is necessary before initiation of maintenance therapy. It may be accomplished with either oral or rectal medication (Fig. 1, box 7). In uncontrolled clinical trials, disimpaction by the oral route, the rectal route, or a combination of the two has been shown to be effective (Table 7) (20). There are no randomized studies that compare the effectiveness of one with the other. The oral approach is not invasive and gives a sense of power to the child, but adherence to the treatment regimen may be a problem. The rectal approach is faster but is invasive. The choice of treatment is best determined after discussing the options with the family and child.
Disimpaction with oral medication has been shown to be effective when high doses of mineral oil, polyethylene glycol electrolyte solutions, or both are used, (20-24). Although there are no controlled trials demonstrating the effectiveness of high-dose magnesium hydroxide, magnesium citrate, lactulose, sorbitol, senna, or bisacodyl for initial disimpaction, these laxatives have been used successfully in that role (25,26). It is recommended that mineral oil, oral electrolyte solutions, or the listed laxatives be used alone or in combination for initial disimpaction when the oral route is selected.
Rectal disimpaction may be performed with phosphate soda enemas, saline enemas, or mineral oil enemas followed by a phosphate enema (27,28). These enemas are widely used and are effective. The use of soapsuds, tap water, and magnesium enemas is not recommended because of their potential toxicity. Rectal disimpaction has also been effectively performed with glycerin suppositories in infants (29) and bisacodyl suppositories in older children.
The Committee discussed the use of digital disimpaction in chronic constipation in the primary care setting. However, there was insufficient literature on the subject, and the Committee could not reach consensus on whether to discourage or recommend its use.
Once the impaction has been removed, the treatment focuses on the prevention of recurrence. In the child who has no impaction (Fig. 1, box 9) or after successful disimpaction, maintenance therapy is begun. This treatment consists of dietary interventions, behavioral modification, and laxatives to assure that bowel movements occur at normal intervals with good evacuation.
Dietary changes are commonly advised, particularly increased intake of fluids and absorbable and nonabsorbable carbohydrate, as a method to soften stools. Carbohydrates and especially sorbitol, found in some juices such as prune, pear, and apple juices, can cause increased frequency and water content of stools (30,31). There are conflicting reports about the role of dietary fiber, with evidence that constipated children have a lower, equivalent or higher intake of dietary fiber (32-35). Administration of glucamomannan (36) in addition to laxatives may be beneficial in the treatment of constipation. Until additional studies demonstrate the efficacy of treatment with fiber, the current findings are too weak to support a definitive recommendation for fiber supplementation in the treatment of constipation. A balanced diet that includes whole grains, fruits, and vegetables is recommended as part of the treatment for constipation in children. Forceful implementation of diet is undesirable.
An important component of treatment includes behavior modification and regular toilet habits (37). Unhurried time on the toilet after meals is recommended. As part of the treatment of constipation, with or without overflow incontinence, it is often helpful to have children and their caregivers keep diaries of stool frequency. This can be combined with a reward system. For example, a child can use a calendar with stickers to record each stool that is passed in the toilet. The calendar can then be taken on visits with the health-care provider and can serve as both a diary and a point for positive reinforcement. In cases in which motivational or behavioral problems are interfering with successful treatment, referral to a mental health-care provider for behavior modification or other intervention may be helpful.
The successful treatment of constipation, especially with overflow incontinence, requires a family that is well organized, can complete time-consuming interventions, and is sufficiently patient to endure gradual improvements and relapses. Close follow-up by telephone and by office visit is recommended. Some families may need counseling to help them manage this problem effectively.
It is often necessary to use medication to help constipated children achieve regular bowel movements (Table 7). A prospective, randomized trial showed that the addition of medications to behavior management in children with constipation is beneficial (38). Children who received medications achieved remission significantly sooner than children who did not. The use of laxatives was most advantageous for children until they were able to maintain regular toilet habits.
When medication is necessary in the daily treatment of constipation, mineral oil (a lubricant) or magnesium hydroxide, lactulose, sorbitol, polyethylene glycol (PEG) (osmotic laxatives), or a combination of lubricant and laxative is recommended. At this stage in the treatment of constipation, the prolonged use of stimulant laxatives is not recommended. Extensive experience with long-term use of mineral oil (39), magnesium hydroxide (40), and lactulose or sorbitol (40) has been reported. Long-term studies show that these therapies are effective and safe (9,40,41). PEG 3350 appears to be superior to other osmotic agents in palatability and acceptance by children (42-49). Preliminary clinical data in 12 infants suggest that administration of PEG 3350 to infants is effective with no adverse effects noted (50). Further studies are needed before widespread use can be recommended in infants. The doses and potential adverse effects of these medications are found in Table 7. Because mineral oil, magnesium hydroxide, lactulose, or sorbitol seem to be equally efficacious, the choice among these is based on safety, cost, the child's preference, ease of administration, and the practitioner's experience (Fig. 1, box 14).
A stimulant laxative may be necessary intermittently, for short periods, to avoid recurrence of an impaction (Fig. 1, box 15) (51). In this situation the use of stimulant laxatives is sometimes termed rescue therapy.
Maintenance therapy may be necessary for many months. Only when the child has been having regular bowel movements without difficulty is discontinuation considered. Primary care providers and families should be aware that relapses are common and that difficulty with bowel movements may continue into adolescence. Long-term follow-up studies have demonstrated that a significant number of children continue to require therapy to maintain regular bowel movements (52,53)
CONSULTATION WITH A SPECIALIST
Consultation with a pediatric gastrointestinal specialist becomes necessary when the therapy fails, when there is concern that an organic disease exists, or when management is complex (Fig. 1, box 20). A consultant can re-evaluate the child with nonresponding constipation, exclude an underlying organic process, perform specialized tests, and offer counseling. The pediatric gastroenterologist (Fig. 1, boxes 21-23) can review previous therapies, consider using different or additional medications or higher doses of the current medications, and reassess previous management before performing additional studies (Fig. 1, box 23).
A careful review by the primary care practitioner of the differential diagnosis (Table 4) of the organic causes of constipation may be helpful at this time to determine which laboratory tests are indicated before referral to a specialist. It is recommended that the primary care physician consider whether the children who require evaluation by a specialist should have blood tests to identify evidence of hypothyroidism, hypercalcemia, celiac disease, and lead toxicity (Fig. 1, box 16). By having these tests ordered by the primary care provider just before referral to a pediatric gastroenterologist, patients who are found to have a medical problem that requires evaluation by a different subspecialist can be referred directly to the appropriate subspecialist. For example, a child with hypothyroidism can be referred directly to a pediatric endocrinologist.
Abdominal Radiograph and Transit Time
An abdominal radiograph is not indicated to establish the presence of fecal impaction if the rectal examination reveals the presence of large amounts of stool. A retrospective study in children manifesting encopresis showed that a moderate to large amount of stool found on rectal examination has high sensitivity and positive predictive value (greater than 80%) for fecal retention determined by abdominal radiograph, even using the radiologist's subjective interpretation (54). However, the specificity and negative predictive value were 50% or less. When the systematic scoring system developed by Barr et al (19) was used for the presence of fecal retention on radiograph, the sensitivity of moderate to large amounts of stool on rectal examination improved to 92%, and the positive predictive value was 94%. However, the specificity remained at only 71%, and the negative predictive value was only 62% (55).
This suggests that, when there is doubt about whether the patient is constipated, a plain abdominal radiograph is reliable in determining the presence of fecal retention in the child who is obese or refuses a rectal examination, or in whom there are other psychological factors (sexual abuse) that make the rectal examination too traumatic. It may also be helpful in the child with a good history for constipation who does not have large amounts of stool on rectal examination (Fig. 1, box 23). In a recent study the value of the Barr score was compared with the colonic transit time. The Barr score was shown to be poorly reproducible, with low interobserver and intraobserver reliability, and there was no correlation with measurements of transit time (55).
Some patients have a history of infrequent bowel movements but have no objective findings of constipation. The history obtained from the parents and child may not be entirely accurate (56). In these patients an evaluation of colonic transit time with radiopaque markers may be helpful (Fig. 1, box 25) (57). The quantification of transit time shows whether constipation is present and provides an objective evaluation of bowel movement frequency. If the transit time is normal, the child does not have constipation. If the transit time is normal and there is no soiling, the child needs no further evaluation (Fig. 1, box 30). In children who have soiling without evidence of constipation, the best results have been achieved with behavior modification, but in some instances psychological evaluation and treatment may be necessary (Fig. 1, box 29). If the transit study is abnormal or fecal impaction is present, further evaluation is needed (Fig. 1, box 26). When there is objective evidence of constipation and it is refractory to treatment, it is important to consider Hirschsprung disease (Fig. 1, box 28).
Hirschsprung disease is the most common cause of lower intestinal obstruction in neonates and is a rare cause of intractable constipation in toddlers and school-aged children (52,58-60). It is characterized by absence of ganglion cells in the myenteric and submucous plexuses of the distal colon, resulting in sustained contraction of the aganglionic segment. The aganglionic segment begins at the internal anal sphincter, extending orad in a contiguous fashion. In 75% of cases, the disease is limited to the rectosigmoid area. The bowel proximal to the aganglionic zone becomes dilated because of the distal obstruction.
The incidence of Hirschsprung disease is approximately 1 in 5000 live births. The most common associated abnormality is trisomy 21. More than 90% of normal neonates and less than 10% of children with Hirschsprung disease pass meconium in the first 24 hours of life (61,62). Thus, a delayed passage of meconium by a full-term infant raises the suspicion of Hirschsprung disease. Hirschsprung disease can have symptoms of bilious vomiting, abdominal distension, and refusal to feed, all of which are suggestive of intestinal obstruction. Short-segment Hirschsprung disease may go undiagnosed until childhood. Affected children have ribbon-like stools, a distended abdomen, and, often, failure to thrive. In rare cases constipation is the only symptom. Fecal soiling is even more rare and occurs only when the aganglionic segment is extremely short.
Enterocolitis, the most feared complication of Hirschsprung disease, may be its initial manifestation. Enterocolitis has initial symptoms of sudden onset of fever, abdominal distension, and explosive and at times bloody diarrhea (63,64). Occurring most often during the second and third months of life, it is associated with a mortality of 20%. The incidence of enterocolitis can be greatly reduced by a timely diagnosis of Hirschsprung disease.
The mean age at diagnosis decreased from 18.8 months in the 1960s to 2.6 months in the 1980s because of physicians' vigilance, anorectal manometry, and early biopsy. However, in 8% to 20% of children, Hirschsprung disease remains unrecognized after the age of 3 years (65,66). Physical examination reveals a distended abdomen and a contracted anal sphincter and rectum in most children. The rectum is devoid of stool except in cases of short-segment aganglionosis. As the finger is withdrawn, there may be an explosive discharge of foul- smelling liquid stools, with decompression of the proximal normal bowel. In the older child with constipation, a careful history and a thorough physical examination are sufficient to differentiate Hirschsprung disease from functional constipation in most cases.
Once Hirschsprung disease is suspected (Fig. 1, box 28), it is recommended that the patient be evaluated at a medical center in which a pediatric gastroenterologist and a pediatric surgeon are available and where diagnostic studies can be performed. Delay in diagnosis increases the risk of enterocolitis. Rectal biopsy with histopathologic examination and rectal manometry are the only tests that can reliably exclude Hirschsprung disease. Rectal biopsies demonstrating the absence of ganglion cells in the submucosal plexus are diagnostic of Hirschsprung disease (67). The biopsies, obtained approximately 3 cm above the anal verge, must be deep enough to include adequate submucosa. The presence of hypertrophied nerves supports the diagnosis. However, in total colonic aganglionosis there is both an absence of ganglion cells and an absence of hypertrophied nerves. Occasionally, suction biopsies are not diagnostic, and a full-thickness biopsy is necessary.
Anorectal manometry (Fig. 1, box 31) evaluates the response of the internal anal sphincter to inflation of a balloon in the internal anal sphincter (68). When the rectal balloon is inflated, there is normally a reflex relaxation of the internal anal sphincter. In Hirschsprung disease this rectoanal inhibitory reflex is absent; there is no relaxation, or there may even be paradoxical contraction, of the internal anal sphincter. In a cooperative child, anorectal manometry represents a sensitive and specific diagnostic test for Hirschsprung disease. It is particularly useful when the aganglionic segment is short and results of radiologic or pathologic studies are equivocal. If sphincter relaxation is normal, Hirschsprung disease can be reliably excluded. In the presence of a dilated rectum, it is necessary to inflate the balloon with large volumes to elicit normal sphincter relaxation. In the child with retentive behavior, there may be artifacts caused by voluntary contraction of the external anal sphincter and the gluteal muscles. Sedation, which does not interfere with the rectoanal inhibitory reflex, may be used in newborns and uncooperative children. If manometry results are abnormal, diagnosis should be confirmed with a biopsy.
Although a barium enema is often performed as the initial screening test to rule out Hirschsprung disease, it is usually unnecessary beyond infancy (69). When stool is present in the rectum to the level of the anus, the barium enema provides no more useful information than can be obtained with a plain radiograph. However, after the diagnosis of Hirschsprung disease has been made, the barium enema may be useful in identifying the location of the transition zone, provided that laxatives or enemas have not been administered before the study to clean out the colon. The barium enema may not show a transition zone in cases of total colonic Hirschsprung disease, or may be indistinguishable from cases of functional constipation when ultra-short-segment Hirschsprung disease is present.
Other Medications and Testing
If constipation is not resolved with the treatments outlined above, and Hirschsprung disease has been excluded, other therapies may be considered (Fig. 1, box 34). Clearly, treatment may be necessary for an extended period-months or years. Stimulant laxatives can be added for short periods. There is extensive experience with senna, bisacodyl, and phenolphthalein (70,71). However, phenolphthalein is no longer available in the United States because of concerns about its carcinogenic potential.
For most children with constipation the benefits of cisapride do not outweigh the risks (72-75). The committee does not recommend its use.
Biofeedback therapy has been evaluated in multiple open-label studies in which it was found to be efficacious (76). Results in some recent controlled studies, however, did not demonstrate long-term efficacy. Biofeedback may be beneficial for the treatment of a small subgroup of patients with intractable constipation (77-79). At times intensive psychotherapy may be needed. On rare occasion, hospital admission with behavioral therapy may be necessary.
Many conditions can cause constipation (Table 4). For children who remain constipated despite conscientious adherence to the treatments outlined, other tests may be indicated (Fig. 1, box 38). Magnetic resonance imaging (MRI) of the lumbosacral spine can demonstrate intraspinal problems, such as a tethered cord, tumors, or sacral agenesis (80). Other diagnostic tests such as anorectal manometry, rectal biopsy, colonic manometry, barium enema, and a psychological evaluation can be helpful. Colonic manometry, by providing objective evidence of colonic function, can exclude the presence of underlying neuropathy or myopathy and may guide therapeutic intervention (81-83). Barium enema can be useful to exclude the presence of anatomic abnormalities or of a transition zone. Full-thickness rectal biopsy can be useful to detect neuronal intestinal dysplasia or other myenteric abnormalities, including Hirschsprung disease. Metabolic tests, such as serum calcium level, thyrocalcitonin concentration, or thyroid function tests, can detect metabolic causes of constipation (84).
For children unresponsive to conventional medical and behavioral management consideration may be given to a time limited trial of cow's milk free diet (85-88)
ALGORITHM FOR INFANTS LESS THAN 1 YEAR OF AGE
The evaluation of infants differs in some aspects from that of older children. Even in infancy, most constipation is functional. However, when treatment fails, when there is delayed passage of meconium (Fig. 2, box 4), or when red flags are present (Fig. 2, box, 8), particular consideration of Hirschsprung disease and other disorders is necessary. Hirschsprung disease has been described in detail. In a constipated infant with delayed passage of meconium, if Hirschsprung disease has been excluded, it is recommended that a sweat test be performed to rule out cystic fibrosis (Fig. 2, box 6). Constipation can be an early manifestation of cystic fibrosis, even in the absence of failure to thrive and pulmonary symptoms.
Special consideration should also be given to breast-fed infants in the first year of life. Greater variability in stool frequency occurs among breast-fed infants than in formula-fed infants (4,89,90). Unless suspicion of Hirschsprung disease is present, management of a breast-fed infant requires only reassurance and close follow-up if the infant is growing and breast-feeding normally and has no signs or symptoms of obstruction or enterocolitis.
Some important differences in treatment of constipation in infants include increased intake of fluids, particularly of juices containing sorbitol, such as prune, pear, and apple juices, which is recommended within the context of a healthy diet. Barley malt extract, corn syrup, lactulose, or sorbitol can be used as stool softeners. Light and dark corn syrups are not considered to be potential sources of Clostridium botulinum spores (91). Mineral oil, stimulant laxatives and phosphate enemas are not recommended. Because gastroesophageal reflux and incoordination of swallowing are more common in infants, there is greater risk of aspiration of mineral oil, which can induce severe lipoid pneumonia (92-94). Glycerin suppositories can be useful, and enemas are to be avoided.
Constipation Guideline Committee of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition
Susan S. Baker, MD, Chair
Gregory S. Liptak, MD
Richard B. Colletti, MD
Joseph M. Croffie, MD
Carlo DiLorenzo, MD
Walton Ector, MD
Samuel Nurko, MD
1. Molnar D, Taitz LS, Urwin OM, Wales JK. Anorectal manometry results in defecation disorders. Arch Dis Child
2. Nyhan WE. Stool frequency of normal infants in the first weeks of life. Pediatrics
3. Weaver LT, Steiner H. The bowel habits of young children. Arch Dis Child
4. Hyams JS, Treem WR, Etienne NL, et al. Effect of infant formula on stool characteristics of young infants. Pediatr
5. Partin JC, Hamill SK, Fischel JE, Partin JS. Painful defecation and fecal soiling in children. Pediatr
6. Borowitz SM, Cox DJ, Tam A, Ritterband LM, Sutphen JL, Penberthy JK. Precipitants of constipation
during early childhood. J Amer Board Fam Pract
7. Hyman PE, Fleisher D. Functional fecal retention. Pract Gastroenterol
(on-line database) Bethesda, MD: National Library of Medicine, 1989. Updated weekly. Available from National Library of Medicine; BRS Information Technologies, McLean, VA: DIALOG Information Services, Inc., Palo Alto, CA
9. Mulrow CD, Oxman AD, eds. Formulating the problem. Cochrane Collaboration Handbook (updated September, 1997); Section 4. In: The Cochrane Library
(database on disk and CDROM). Cochrane Collaboration. Oxform: Update Software; 1997, issue 4; Appendix 5c.2; available at http://www.medlib.com/cochranehandbook/
10. Sackett DL, Haynes B, Tugwell P. Clinical epidemiology: A basic science for clinical medicine
, 2nd. Boston: Little, Brown, 1991.
11. Evidence-Based Medicine Informatics Project. Evidence based medicine: Users' guides to the medical literature.
Available at http://hiru.mcmaster.ca/ebm/userguid/
, revised, May, 1997
12. Liptak GS. Tethered spinal cord: an analysis of clinical research. Eur J Pediatr Surg
13. Liptak GS. Tethered spinal cord: Update of an analysis of published articles. Eur J Pediatr Surg
14. Canadian Task Force on the Periodic Health Examination. The periodic health examination. Can Med Assoc J
15. McMurray AR. Three decision-making aids: Brainstorming, nominal group, and delphi technique. J Nurs Staff Dev
16. Fisher M, Eckhard C, eds. Guide to clinical preventive services: an assessment of the effectiveness of 169 interventions. Report of the US Preventive Services Task Force
. Baltimore: Williams and Wilkins, 1989:387-8.
17. Potts MJ, Sesney J. Infant constipation
: Maternal knowledge and beliefs. Clin Pediatr
18. Rappaport LA, Levine MD. The prevention of constipation
and encopresis: A developmental model and approach. Pediatr Clin North Am
19. Barr RG, Levine MD, Wilkinson RH, Mulvihill D. Chronic and occult stool retention: A clinical tool for its evaluation in school-aged children. Clin Pediatr
20. Tolia V, Lin CH, Elitsur Y. A prospective randomized study with mineral oil and oral lavage solution for treatment of faecal impaction in children. Aliment Pharmacol Ther
21. Gleghorn EE, Heyman MB, Rudolph CD. No-enema therapy for idiopathic constipation
and encopresis. Clin Pediatr
22. Ingebo KB, Heyman MB. Polyethylene glycol-electrolyte solution for intestinal clearance in children with refractory encopresis: A safe and effective therapeutic program. Am J Dis Child
23. Youssef NN, Peters JM, Henderson W, Shultz-Peters S, Lockhart DK, DiLorenzo C. Dose response of PEG 3350 for the treatment of childhood fecal impaction. J Pediatr
24. Ferguson A, Culbert P, Gillett H, Barras N. New polyethylene glycol electrolyte solution for the treatment of constipation
and faecal impaction. Ital J Gastroenterol Hepatol
25. Sutphen JL, Borowitz SM, Hutchison RL, Cox DJ. Long-term follow-up of medically treated childhood constipation
. Clin Pediatr
26. Loening-Baucke V. Modulation of abnormal defecation dynamics by biofeedback treatment in chronically constipated children with encopresis. J Pediatr
27. Nurko SS, Garcia-Aranda JA, Guerrero VY, Woroma LB. Treatment of intractable constipation
in children: Experience with cisapride. J Pediatr Gastroenterol Nutr
28. Cox DJ, Sutphen J, Borowitz S, Dickens MN, Singles J, Whitehead WE. Simple electromyographic biofeedback treatment for chronic pediatric constipation
/encopresis: Preliminary report. Biofeedback Self Regul
29. Weisman LE, Merenstein GB, Digirol M, Collins J, Frank G, Hudgins C. The effect of early meconium evacuation on early-onset hyperbilirubinemia. Am J Dis Child
30. Kneepkens CMF. What happens to fructose in the gut? Scand J Gastroenterol
31. Gryboski JD. Diarrhea from dietetic candy. N Engl J Med
32. Roma E, Adamidis D, Nikolara R, Constantopoulos A, Messaritakis J. Diet and chronic constipation
in children: the role of fiber. J Pediatr Gastroenterol Nutr
33. Moaris MB, Vitolo MR, Aguirre ANC, Fagundes-Neto U. Measurement of low-dietary fiber intake as a risk factor for chronic constipation
in children. P Pediatr Gastroenterol Nutr
34. Guimaraes EV, Goulart EMA, Penna FJ. Dietary fiber intake, stool frequency and colonic transit time in chronic functional constipation
in children. Brazil J Med Biol Res
35. Speridiao PGL, Tahan S, Fagundes-Neto U, Morais MB. Dietary fiber, energy intake and nutritional status during the treatment of children with chronic constipation
. Brazil J Med Biol Res
36. Loening-Baucke V, Miele E, Staiano A. Fiber (glucomannan) is beneficial in the treatment of childhood constipation
37. Lowery SP, Srour JW, Whitehead WE, Schuster NM. Habit training as treatment of encopresis secondary to chronic constipation
. J Pediatr Gastroenterol Nutr
38. Nolan T, Debelle G, Oberklaid F, Coffey C. Randomized trial of laxatives in treatment of childhood encopresis. Lancet
39. McClung HJ, Boyne LJ, Linsheid T, et al. Is combination therapy for encopresis nutritionally safe. Pediatr
40. Loening-Baucke V. Chronic constipation
in children. Gastroenterol
41. Clark JH, Russell GJ, Fitzgerald JF, Nagamori KE. Serum β-carotene, retinol, and α-tocopherol levels during mineral oil therapy for constipation
. Am J Dis Child
42. Staiano A. Use of polyethylene glycol solution in functional and organic constipation
in children. Ital J Gastroenterol Hepatol
43. Loening-Baucke V. Polyethylene glycol without electrolytes for children with constipation
and encopresis. J Pediatr Gastroenterol Nutr
44. Pashankar DS, Bishop WP. Efficacy and optimal dose of daily polyethylene glycol 3350 for treatment of constipation
and encopresis in children. J Pediatr
45. Gremse DA, Hixon J, Crutchfield A. Comparison of polyethylene glycol 3350 and lactulose for treatment of chronic constipation
in children. Clin Pediatr
46. Pashankar DS, Loening-Baucke V, Bishop WP. Safety of polyethylene glycol 3350 for the treatment of chronic constipation
in children. Arch Pediatr Adolesc Med
47. Bell EA, Wall GC. Pediatric constipation
therapy using guidelines
and polyethylene glycol 3350. Ann Pharmacother
48. Erickson BA, Austin JC, Cooper CS, Boyt MA. Polythylene glycol 3350 for constipation
in children with dysfunctional elimination. J Urol
49. Pashankar DS, Bishop WP, Loening-Baucke V. Long-term efficacy of polyethylene glycol 3350 for the treatment of chronic constipation
in children with and without encopresis. Clin Pediatr
50. Michail S, Gendy E, Preud'Homme D, Mezoff A. Polyethylene glycol for constipation
in children younger than eighteen months old. J Pediatr Gastroenterol Nutr
51. Nurko SS. Constipation
. In: Walker-Smith J, Hamilton D, Walker AW eds. Practical Pediatric Gastroenterology
, 2nd ed. Hamilton, Ontario: BC Decker, 1996:95-106.
52. Staiano A, Andreotti MR, Greco L, Basile P, Auricchio S. Long term follow up of children with chronic idiopathic constipation
. Dig Dis Sci
53. Loening-Baucke V. Constipation
in children. Curr Opin Pediatrics
54. Rockney RM, McQuade WH, Days AL. The plain abdominal roentgenogram in the management of encopresis. Arch Pediatr Adolesc Med
55. Benninga MA, Buller HA, Staalman CR, et al. Defecation disorders in children, colonic transit vs the Barr score. Eur J Pediatr
56. Van der Plas RN, Benninga MA, Redekop WK, Taminiau JA, Buller HA. How accurate is the recall of bowel habits in children with defaecation disorders? Eur J Pediatr
57. Papadopoulou A, Clayden GS, Booth IW. The clinical value of solid marker transit studies in childhood constipation
and soiling. Eur J Pediatr
58. Keinhaus S, Boley SJ, Sheran M, Sieber WK. Hirschsprung's disease: A survey of the members of the surgical section of the American Academy of Pediatrics. J Pediatr Surg
59. Russell MB, Russell CA, Niebuhr E. An epidemiological study of Hirschsprung's disease and additional anomalies. Acta Paediatr
60. Reding R, de Ville de Goyet J, Gosseye S, et al. Hirschsprung's disease: A 20 year experience. J Pediatr Surg
61. Sherry SN, Kramer I. The time of passage of the first stool and first urine in the newborn infant. J Pediatr
62. Clark DA. Times of first void and first stool in 500 newborns. Pediatr
63. Marty TL, Matlak ME, Hendrickson M, Black RE, Johnson DG. Unexpected death from enterocolitis after surgery for Hirschsprung's disease. Pediatr
64. Elhalaby EA, Teitelbaum DH, Coran AG, Heidelberger KP. Enterocolitis associated with Hirschsprung's disease: A clinical histopathological correlative study. J Pediatr Surg
65. Klein MD, Phillippart AL. Hirschsprung's disease: Three decades experience at a single institution. J Pediatr Surg
66. Swenson O, Sherman JO, Fisher JH. Diagnosis of congenital megacolon: An analysis of 501 patients. J Pediatr Surg
67. Aldridge RT, Campbell PE. Ganglion cells distribution in the normal rectum and anal canal: A basis for diagnosis of Hirschsprung's disease by anorectal biopsy. J Pediatr Surg
68. Rosemberg AJ, Vela AR. A new simplified technique for pediatric anorectal manometry. Pediatrics
69. Taxman TL, Yulish BS, Rothstein FC. How useful is the barium enema in the diagnosis of infantile Hirschsprung's disease? Am J Dis Child
70. Berg I, Forsythe I, Holt P, Watts J. A controlled trial of "Senokot" in faecal soiling treated by behavioral methods. J Child Psychol Psychiatry
71. Loening-Baucke VA, Younoszai MK. Effect of treatment on rectal and sigmoid motility in chronically constipated children. Pediatrics
72. Nurko S, Garcia-Aranda JA, Woron LB, Zlochistry O. Cisapride for the treatment of constipation
in children: a double-blind study. J Pediatr
73. Halabi IM. Cisapride in management of chronic pediatric constipation
. Journal of Pediatric Gastroenterology & Nutrition
74. Staiano A, Andreotti MR, Greco L, Basile P, Auricchio S. Long term follow up of children with chronic idiopathic constipation
. Dig Dis Sci
75. Odeka EB, Sagher F, Miller V, Doig C. Use of cisapride in treatment of constipation
in children. Journal of Pediatric Gastroenterology & Nutrition
76. Loening-Baucke V. Biofeedback therapy for chronic constipation
and encopresis in childhood: Long term outcome. Pediatr
77. Loening-Baucke V. Biofeedback training in children with constipation
: A critical review. Dig Dis Sci
78. Van der Plas RN, Benninga MA, Redekop WK, Taminiau JA, Buller HA. Randomized trial of biofeedback training for encopresis. Arch Dis Child
79. Van der Plas RN, Benninga MA, Buller HA, et al. Biofeedback training in treatment of childhood constipation
: A randomized controlled study. Lancet
80. Rosen R, Buonomo C, Andrade R, Nurko S. Incidence of spinal cord lesions in patients with intractable constipation
. J Pediatr
81. DiLorenzo C, Flores AF, Reddy SN, Hyman PE. Use of colonic manometry differentiates causes of intractable constipation
in children. J Pediatr
82. Martin MJ, Steele SR, Mullenix PS, Noel JM, Weichmann D, Azarow KS. A pilot study using total colonic manometry in the surgical evaluation of pediatric functional colonic obstruction. J Pediatr Surg
83. Pensabene L, Youssef NN, Griffiths JM, DiLorenzo C. Colonic manometry in children with defacatory disorders. Role in diagnosis and management. Am J Gastroenterol
84. De Krijer RR, Brooks A, Van Der Harst E, et al. Constipation
as the presenting symptom in de novo multiple endocrine neoplasia type 2B. Pediatr
85. Silva D, Soraia T, Dirceu S, Naspitz CK, DaSilva P, Francy R, Neto UF, MeMorais MB. Cow's milk protein intolerance and chronic constipation
in children. Pediatr Allergy and Immuno
86. Iacono G, Cavataio F, Moltalto G, Florena A, Tumminello M, Soresi M, Notarbartolo A, Carroccio A. Intolerance of cow's milk and chronic constipation
in children. N Engl J Med
87. Carroccio A, Montalt G, Custro N, Notarbartolo A, Cavataio F, D'Amico D, Alabrese L, Iacono G. Evidence of very delayed clinical reactions to cow's milk in cow's milk-intolerant patients. Allergy
88. Andiran F, Dayi S, Mete E. Cows milk consumption in constipation
and anal fissure in infants and young children. J Paediatr Child Health
89. Fontana M, Bianchi C, Cataldo F, et al. Bowel frequency in healthy children. Acta Paediatr Scand
90. Sievers E, Oldigs H-D, Schultz-Lell G, Schaub J. Faecal excretion in infants. Eur J Pediatr
91. Committee on Infectious Diseases, American Academy of Pediatrics. Red Book
. Elk Grove Village, IL: American Academy of Pediatrics, 1997:175.
92. Fan LL, Graham LM. Radiological cases of the month. Lipoid pneumonia from mineral oil aspiration. Arch Pediatr Adolesc Med
93. Rabah R, Evans RW, Yunis EJ. Mineral oil embolization and lipid pneumonia in an infant treated for Hirschsprung's disease. Pediatr Pathol
94. Wolfson BJ, Allen JL, Panitch HB, Karmazin N. Lipid aspiration pneumonia due to gastroesophageal reflux. A complication of nasogastric lipid feedings. Pediatr Radiol
95. . In: Fisher M, Eckhard C eds. Guide to clinical preventive services: an assessment of the effectiveness of 169 interventions. Report of the U.S. Preventive Services Task Force
. Baltimore: Williams & Wilkins, 1989:387-8.
96. Bar-Maor JA, Eitan A. Determination of the normal position of the anus (with reference to idiopathic constipation
). J Pediatr Gastroenterol Nutr
Keywords:© 2006 Lippincott Williams & Wilkins, Inc.